Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting-Reference-Cited by-同舟云学术

Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting

Published:2018-03-12 Issue:6 Volume:55 Page:557-568
ISSN:0940-5429
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Simioni N., ,Berra C.,Boemi M.,Bossi A. C.,Candido R.,Di Cianni G.,Frontoni S.,Genovese S.,Ponzani P.,Provenzano V.,Russo G. T.,Sciangula L.,Lapolla A.,Bette C.,Rossi M. C.^ORCID

Funder

Novo Nordisk A/S

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00592-018-1124-0/fulltext.html

Reference25 articles.

1. Victoza® summary of product characteristics (2016)

2. Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473–481

3. Marre M, Shaw J, Brändle M et al (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26:268–278

4. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 3:84–90

5. Zinman B, Gerich J, Buse JB et al (2009) Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met + TZD). Diabetes Care 32:1224–1230

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Add-on Once-Daily Liraglutide (1.2 mg) in Type 2 Diabetes Patients with Obesity: Data from a Real-World Cohort of Iraqi Patients;Clinical Diabetology;2024-06-30

2. Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study;Diabetes Therapy;2024-03-18

3. Metabolic disorders affecting the liver and heart: Therapeutic efficacy of miRNA-based therapies?;Pharmacological Research;2024-03

4. Biomarkers navigate drug development: Pharmacology, effectiveness and safety;Medicine in Drug Discovery;2024-02

5. Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review;Communications Medicine;2023-10-05